Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. - Wikidata - awgldk - TriplyDB

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

http://www.wikidata.org/entity/Q34837305

about

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice cAMP-responsive element modulator (CREM)α protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus The many roles of histone deacetylases in development and physiology: implications for disease and therapy HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases Histone deacetylases as targets for treatment of multiple diseases Small molecules in the treatment of systemic lupus erythematosus Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial The type 1 diabetes - HLA susceptibility interactome--identification of HLA genotype-specific disease genes for type 1 diabetes.Metabolic control of the epigenome in systemic Lupus erythematosus.Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes.Pathogenic mechanisms in systemic lupus erythematosus.Oxidative stress in the pathology and treatment of systemic lupus erythematosus The biology of reactive intermediates in systemic lupus erythematosus.The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy.Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice.Therapeutic potential of trichostatin A to control inflammatory and fibrogenic disorders of the ocular surface.Epigenetics of autoantigens: new opportunities for therapy of autoimmune diseases.The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo Murine models of systemic lupus erythematosus Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells Potential of epigenetic therapies in non-cancerous conditions.Cubilin expression is monoallelic and epigenetically augmented via PPARs.Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism The epigenetics of autoimmunity.Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).HDAC inhibition in lupus models.HDAC inhibition and graft versus host disease Histone deacetylase regulation of immune gene expression in tumor cells.Biomarker profiling for lupus nephritis.Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions T cells as a therapeutic target in SLE.Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.

P2860

Q24288997-B82269A1-B7A3-4539-91CC-B18CF3BF70FD Q24339465-BD067D26-F291-4F4A-8D94-F97F3E278C3E Q24628821-19905F63-702E-412A-8E4B-68D09E05BC3A Q26739120-CA6FB0B6-2436-462B-9791-0DD12228CE58 Q27000389-776EF9C9-924A-46E5-B837-0956113F34F5 Q27010090-F82A5586-D65D-4B4B-9C88-9A2225AC4E45 Q27324527-ABFE8363-8017-44EE-93F8-D397287C98AD Q28079715-D833AA4E-AF6E-40C7-992D-A6965889B8FD Q28289793-9DA56D3D-190B-4EB2-BAB8-3B948C0DCF64 Q33411822-3CCEAA86-D3C2-43D3-A117-57AEFB84FD88 Q33539771-7DC14654-5D80-4C76-8E47-574F1BF6C1E2 Q33664849-9B9CE48C-167A-4C39-819B-560A18DE3BA3 Q33703372-8B98DE66-146D-461A-8606-D0616EBACFF0 Q33715441-DC3EB12F-862F-44E4-9771-0D7D5C98D652 Q33715508-7F823D16-932C-4644-B67C-144A2B891095 Q33802441-4C31914A-1400-4687-9A54-9E9D4A368FA2 Q33830937-1B57B685-956D-44AB-A253-42B179F95977 Q33908254-5607E88D-AE97-4DE9-8FC7-DA8A097F1845 Q34152949-0CCBEA5F-982F-4EBE-A40F-7627699DC5BE Q34285479-73911B5E-B3A4-436B-8779-414034E593BC Q34452923-46700A8F-ED32-4226-9267-6D09E4E7A8CF Q34463063-82F47317-C359-4A24-92F9-69204DE29695 Q34504770-332548CA-9F1B-46AD-882D-587DD6C65996 Q34591019-83AAF8A1-FCB8-4C5A-B440-0B7CB62F1483 Q34656908-03284A34-B5D0-476B-A589-77869E9DA35E Q34742578-D8BDDA75-3B71-4CBB-8B47-EC197620AEAA Q34774905-C9D5DB95-6A72-4447-A74E-2B088D1F8414 Q34839640-A6AFD971-9DAC-4635-986D-2BD9A65F1D39 Q34979322-199850F2-8E7C-45D4-803A-72C7F3BDA8E0 Q35002986-5EDA808F-A3EE-4224-A2D7-FBEA5E8BF5C0 Q35016934-319C1A79-950B-4579-AB9E-09F25DBED99E Q35016969-77351605-8900-4C48-BCE7-0E783E528295 Q35016981-33920B4E-7F4E-420C-A734-0FFA09C925A6 Q35016985-07900032-3127-48A3-A87A-97624C5B9F9D Q35092304-3768AD8F-3E2F-4D2F-9809-D8829CCA149C Q35171894-589C14CF-AF10-4AA6-967A-E2D5771EA2A9 Q35214718-6BC0DCAC-C61A-4E6F-8799-4B6919FA9D6D Q35214963-B84AE491-8778-4FC3-87D7-28277AA4BD39 Q35309505-B3A0CB08-1106-4EEB-99B5-67173BCCBE42 Q35380239-73775DD5-6DCF-4A59-8863-F9A72E234BB9

P2860

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

http://www.wikidata.org/entity/Q34837305

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@ast

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@en

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@nl

type

label

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@ast

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@en

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@nl

prefLabel

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@ast

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@en

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

@nl

P1433

Q34837305-E6327C54-8481-4578-B27A-A685588EF375

P1476

Q34837305-4F2FB219-715E-43C7-9ED7-2B7D50025E3A

P2093

Q34837305-26E0BF36-8F30-4723-A7E2-F604C2AD0EBD

Q34837305-58FBB8BB-A630-40A2-A959-27A069C0F50F

Q34837305-7632E7F0-7C21-4D6C-AD09-C229541960E2

Q34837305-F6E9F6EB-AA01-47A0-AFAC-30C6C81241C1

P2860

Q34837305-04F56374-3601-4073-8165-D8B4B6A9159F

Q34837305-0A4C7306-C2E1-4143-9A6C-E54D64CDB023

Q34837305-0BB5522C-0BBA-44E3-9086-5A49CDBB043D

Q34837305-11DE0AEF-E960-4D5C-955A-DF3499A522A5

Q34837305-15015913-AFED-4B91-BDB4-C914D7A3C575

Q34837305-1F1C521D-02EB-42B2-AA41-99D4DCAD8C6D

Q34837305-21627E2D-AA2A-4172-8970-05AF34F6ADA8

Q34837305-288F1309-AAEF-46B4-9D36-F12FA89C5D02

Q34837305-3377C71B-DF5C-40DB-B06A-2DA158D8FD8C

Q34837305-341AB9FE-1E0B-4ABD-BB6A-BEBEFFD3E037

P304

Q34837305-69EBF34A-8D81-4400-8432-674CA75E44C6

P31

Q34837305-2F4E0843-B1F0-45FE-B45A-F32FD41C6603

P356

Q34837305-1B2CAE0F-6C32-4E48-B9AF-A528E3CBAB9D

Q34837305-61F238B2-F97A-40A9-AF8A-3299BF9A77AE

P407

Q34837305-A4292DC8-2B89-4D55-A48D-BBD3FB344570

P433

Q34837305-0F510332-7749-49F6-B3E0-B9338B26E373

P478

Q34837305-9A765E23-2316-4BB2-9DC4-617D5200ECA2

P50

Q34837305-856A7BDE-A966-4A5A-B266-539B9F9939AE

P577

Q34837305-6EFF8690-180A-4A1A-AE57-D84313376616

P698

Q34837305-F845089B-B141-462D-B150-361844DA7DD0

P932

Q34837305-61D7E1D0-64C7-4E23-81D0-CACACB2A8FF1

P356

P1433

Journal of Clinical Investigation

P1476

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse

@en

P2093

Christopher M Reilly

http://www.w3.org/2001/XMLSchema#string

Gary S Gilkeson

http://www.w3.org/2001/XMLSchema#string

Nilamadhab Mishra

http://www.w3.org/2001/XMLSchema#string

Phil Ruiz

http://www.w3.org/2001/XMLSchema#string

P2860

Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1

Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

Deacetylation of p53 modulates its effect on cell growth and apoptosis

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

Histone deacetylases augment cytokine induction of the iNOS gene

What's up and down with histone deacetylation and transcription?

Structure of the human immune interferon gene

Regulation of immune responses by TGF-beta

P304

539-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI16153

http://www.w3.org/2001/XMLSchema#string

10.1172/JCI200316153

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12588892

http://www.w3.org/2001/XMLSchema#string

P932

151922

http://www.w3.org/2001/XMLSchema#string